Pablo Jiménez, clinical research fellow at the the Royal Marsden Hospital, shared a post on X:
“Eager to review the Ph2 KEYCHAIN presentation about patients with unfavorable-risk p16+ HNSCC Thought-provoking trial in this difficult space to reach a H&N PACIFIC/ADRIATIC protocol as in lung.
Unlike KN412, pembro is replacing cis, not added to CRT.
Radical RT+pembro vs RT+Cis
- 2yPFS: 84vs70%; HR 0.57 (0.25-1.31) p=0.09
- 2yOS: 98vs85%; HR 0.33 (0.09-1.28) p=0.048
- lenient 1-side α=0.15
June 1. HallD1. 4:30.”
Other articles featuring Pablo Jiménez on OncoDaily.